Drug Trial Radar · NCT05930119
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
Last checked: Nov 19, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 17, 2023
Primary completion
Aug 28, 2023
Study completion Aug 28, 2023
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Jul 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers
Conditions
- Intrahepatic Cholangiocarcinoma
Interventions
HMPL-453Drug
300 mg HMPL-453
RabeprazoleDrug
20 mg of rabeprazole will be administered by mouth once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameter for HMPL-453: AUC0-tTime frame: Day 1 to Day 33
- PK parameter for HMPL-453: AUC0-infTime frame: Day 1 to Day 33
- PK parameter for HMPL-453: CmaxTime frame: Day 1 to Day 33
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.